Compounded GLP1s

Shortages, access, and cost have led to compounding GLP1s, which has created confusion and misinformation for patients and healthcare providers. Join us as we discuss this practice and delve into what you need to know as a healthcare provider.THE GAMECHANGER: The advent of GLP1s is a true GameChanger in the health of patients with diabetes, cardiovascular diseases, and obesity, and has led to access issues for manufactured products. GuestsTenille Davis, PharmD, RPhChief Advocacy OfficerAlliance for Pharmacy CompoundingScott Brunner, CAECEOAlliance for Pharmacy CompoundingHostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health Referencehttps://a4pc.org/advocacy/educating-prescribers/https://a4pc.org/advocacy/statements-and-other-resources/https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-March-2024.pdf Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Review criteria for compounding drugs on the FDA drug shortage list. 2. Discuss the facts and misinformation surrounding compounded GLP1 medications.0.05 CEU/0.5 HrUAN: 0107-0000-24-145-H01-PInitial release date: 04/15/2024Expiration date: 04/15/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram